1. Market Research
  2. > Diabetes - Pipeline Review, H2 2013

Diabetes - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 427 pages

Diabetes - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Diabetes - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetes. Diabetes - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetes.
- A review of the Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetes pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diabetes.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetes pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Diabetes - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
Introduction 7
Diabetes Overview 8
Therapeutics Development 9
Diabetes Therapeutics under Development by Companies 11
Diabetes Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 23
Mid Clinical Stage Products 24
Early Clinical Stage Products 25
Discovery and Pre-Clinical Stage Products 26
Diabetes Therapeutics - Products under Development by Companies 27
Diabetes Therapeutics - Products under Investigation by Universities/Institutes 40
Companies Involved in Diabetes Therapeutics Development 41
Diabetes - Therapeutics Assessment 138
Drug Profiles 146
Diabetes Therapeutics - Drug Profile Updates 369
Diabetes Therapeutics - Discontinued Products 393
Diabetes Therapeutics - Dormant Products 394
Diabetes - Product Development Milestones 398
Appendix 405



List of Tables

Number of Products Under Development for Diabetes, H2 2013 30
Products under Development for Diabetes - Comparative Analysis, H2 2013 31
Number of Products under Development by Companies, H2 2013 33
Number of Products under Development by Companies, H2 2013 (Contd..1) 34
Number of Products under Development by Companies, H2 2013 (Contd..2) 35
Number of Products under Development by Companies, H2 2013 (Contd..3) 36
Number of Products under Development by Companies, H2 2013 (Contd..4) 37
Number of Products under Development by Companies, H2 2013 (Contd..5) 38
Number of Products under Development by Companies, H2 2013 (Contd..6) 39
Number of Products under Development by Companies, H2 2013 (Contd..7) 40
Number of Products under Development by Companies, H2 2013 (Contd..8) 41
Number of Products under Investigation by Universities/Institutes, H2 2013 43
Comparative Analysis by Late Stage Development, H2 2013 44
Comparative Analysis by Mid Clinical Stage Development, H2 2013 45
Comparative Analysis by Early Clinical Stage Development, H2 2013 46
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 47
Products under Development by Companies, H2 2013 48
Products under Development by Companies, H2 2013 (Contd..1) 49
Products under Development by Companies, H2 2013 (Contd..2) 50
Products under Development by Companies, H2 2013 (Contd..3) 51
Products under Development by Companies, H2 2013 (Contd..4) 52
Products under Development by Companies, H2 2013 (Contd..5) 53
Products under Development by Companies, H2 2013 (Contd..6) 54
Products under Development by Companies, H2 2013 (Contd..7) 55
Products under Development by Companies, H2 2013 (Contd..8) 56
Products under Development by Companies, H2 2013 (Contd..9) 57
Products under Development by Companies, H2 2013 (Contd..10) 58
Products under Development by Companies, H2 2013 (Contd..11) 59
Products under Development by Companies, H2 2013 (Contd..12) 60
Products under Investigation by Universities/Institutes, H2 2013 61
Bristol-Myers Squibb Company, H2 2013 62
Baxter International Inc., H2 2013 63
Sanofi-Aventis, H2 2013 64
Eli Lilly and Company, H2 2013 65
Athersys, Inc., H2 2013 66
Daiichi Sankyo Company, Ltd, H2 2013 67
Merck and Co., Inc., H2 2013 68
Takeda Pharmaceutical Company Limited, H2 2013 69
Mochida Pharmaceutical Co., Ltd., H2 2013 70
Tissue Repair Company, H2 2013 71
Meytav Technological Incubator, H2 2013 72
Ipsen S.A., H2 2013 73
Piramal Healthcare Limited, H2 2013 74
Astellas Pharma Inc., H2 2013 75
Biocon Limited, H2 2013 76
Dong-A Pharmaceutical Co., Ltd., H2 2013 77
Pfizer Inc., H2 2013 78
Rigel Pharmaceuticals, Inc., H2 2013 79
Zydus Cadila Healthcare Limited, H2 2013 80
Biodel Inc., H2 2013 81
Zosano Pharma, Inc., H2 2013 82
TheraKine Inc., H2 2013 83
Access Pharmaceuticals, Inc., H2 2013 84
Alchemia Limited, H2 2013 85
Insmed Incorporated, H2 2013 86
Genfit, H2 2013 87
Ligand Pharmaceuticals Incorporated, H2 2013 88
Lupin Limited, H2 2013 89
Opexa Therapeutics, Inc., H2 2013 90
Orchid Chemicals and Pharmaceuticals Ltd, H2 2013 91
ConjuChem Biotechnologies Inc., H2 2013 92
Lexicon Pharmaceuticals, Inc., H2 2013 93
Yuhan Corporation, H2 2013 94
Array BioPharma Inc., H2 2013 95
XOMA Ltd., H2 2013 96
Torrent Pharmaceuticals Limited, H2 2013 97
Choongwae Pharma Corp, H2 2013 98
Hanall Pharmaceutical Co., Ltd., H2 2013 99
Ahn-Gook Pharmaceutical Co., Ltd., H2 2013 100
HYUNDAI PHARM. CO., LTD., H2 2013 101
Panacea Biotec Limited, H2 2013 102
Summit Corporation plc, H2 2013 103
Transgene Biotek Ltd, H2 2013 104
DONGKOOK Pharmaceutical Co., Ltd., H2 2013 105
Hybrigenics S.A., H2 2013 106
Digna Biotech, S.L., H2 2013 107
Angelini Group, H2 2013 108
Betagenon AB, H2 2013 109
Sirtris Pharmaceuticals, Inc., H2 2013 110
Jenrin Discovery, Inc., H2 2013 111
Upsher-Smith Laboratories, Inc., H2 2013 112
Evolva SA, H2 2013 113
Phosphagenics Limited, H2 2013 114
Xenon Pharmaceuticals Inc., H2 2013 115
Spherix Incorporated, H2 2013 116
Ambrx, Inc., H2 2013 117
Five Prime Therapeutics, Inc., H2 2013 118
GP Pharm, S.A., H2 2013 119
Diabetology Limited, H2 2013 120
MSM Protein Technologies, Inc., H2 2013 121
Zealand Pharma A/S, H2 2013 122
Indus Biotech Private Limited, H2 2013 123
NOXXON Pharma AG, H2 2013 124
Omeros Corporation, H2 2013 125
Aegis Therapeutics, LLC, H2 2013 126
Peptron, Inc., H2 2013 127
Immunocore Limited., H2 2013 128
Molecular Design International, Inc., H2 2013 129
PepTcell Limited, H2 2013 130
Tris Pharma, Inc., H2 2013 131
USV Limited., H2 2013 132
Vitae Pharmaceuticals, Inc., H2 2013 133
Glucox Biotech, H2 2013 134
Novocell, Inc., H2 2013 135
Diakron Pharmaceuticals, Inc., H2 2013 136
TaiGen Biotechnology Co., Ltd., H2 2013 137
MacuCLEAR, Inc., H2 2013 138
KAHR medical Ltd., H2 2013 139
Johnson and Johnson Pharmaceutical Research and Development, L.L.C., H2 2013 140
Innocoll, Inc., H2 2013 141
Centocor Ortho Biotech, Inc., H2 2013 142
Adocia, H2 2013 143
Amunix, Inc., H2 2013 144
Pharnext SAS, H2 2013 145
NGM Biopharmaceuticals, Inc., H2 2013 146
Amplimmune, Inc., H2 2013 147
DiscoveryBiomed, Inc., H2 2013 148
Signum Biosciences, Inc., H2 2013 149
Q Chip Ltd., H2 2013 150
Nuvilex, Inc., H2 2013 151
Revivicor, Inc., H2 2013 152
Laila Pharmaceuticals Pvt. Ltd., H2 2013 153
PharmaIN Corporation, H2 2013 154
AUS Bio Limited, H2 2013 155
Advancell, H2 2013 156
Madeira Therapeutics, H2 2013 157
Rhythm Pharmaceuticals, H2 2013 158
Assessment by Monotherapy Products, H2 2013 159
Assessment by Combination Products, H2 2013 160
Assessment by Stage and Route of Administration, H2 2013 163
Assessment by Stage and Molecule Type, H2 2013 166
Diabetes Therapeutics - Drug Profile Updates 390
Diabetes Therapeutics - Discontinued Products 414
Diabetes Therapeutics - Dormant Products 415
Diabetes Therapeutics - Dormant Products (Contd..2) 416
Diabetes Therapeutics - Dormant Products (Contd..4) 417
Diabetes Therapeutics - Dormant Products (Contd..6) 418



List of Figures

Number of Products under Development for Diabetes, H2 2013 30
Products under Development for Diabetes - Comparative Analysis, H2 2013 31
Products under Development by Companies, H2 2013 32
Products under Investigation by Universities/Institutes, H2 2013 42
Late Stage Products, H2 2013 44
Mid Clinical Stage Products, H2 2013 45
Early Clinical Stage Products, H2 2013 46
Discovery and Pre-Clinical Stage Products, H2 2013 47
Assessment by Monotherapy Products, H2 2013 159
Assessment by Combination Products, H2 2013 160
Assessment by Route of Administration, H2 2013 161
Assessment by Stage and Route of Administration, H2 2013 162
Assessment by Molecule Type, H2 2013 164
Assessment by Stage and Molecule Type, H2 2013 165



Companies Mentioned

Bristol-Myers Squibb Company
Baxter International Inc.
Sanofi-Aventis
Eli Lilly and Company
Athersys, Inc.
Daiichi Sankyo Company, Ltd
Merck and Co., Inc.
Takeda Pharmaceutical Company Limited
Mochida Pharmaceutical Co., Ltd.
Tissue Repair Company
Meytav Technological Incubator
Ipsen S.A.
Piramal Healthcare Limited
Astellas Pharma Inc.
Biocon Limited
Dong-A Pharmaceutical Co., Ltd.
Pfizer Inc.
Rigel Pharmaceuticals, Inc.
Zydus Cadila Healthcare Limited
Biodel Inc.
Zosano Pharma, Inc.
TheraKine Inc.
Access Pharmaceuticals, Inc.
Alchemia Limited
Insmed Incorporated
Genfit
Ligand Pharmaceuticals Incorporated
Lupin Limited
Opexa Therapeutics, Inc.
Orchid Chemicals and Pharmaceuticals Ltd
ConjuChem Biotechnologies Inc.
Lexicon Pharmaceuticals, Inc.
Yuhan Corporation
Array BioPharma Inc.
XOMA Ltd.
Torrent Pharmaceuticals Limited
Choongwae Pharma Corp
Hanall Pharmaceutical Co., Ltd.
Ahn-Gook Pharmaceutical Co., Ltd.
HYUNDAI PHARM. CO., LTD.
Panacea Biotec Limited
Summit Corporation plc
Transgene Biotek Ltd
DONGKOOK Pharmaceutical Co., Ltd.
Hybrigenics S.A.
Digna Biotech, S.L.
Angelini Group
Betagenon AB
Sirtris Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
Upsher-Smith Laboratories, Inc.
Evolva SA
Phosphagenics Limited
Xenon Pharmaceuticals Inc.
Spherix Incorporated
Ambrx, Inc.
Five Prime Therapeutics, Inc.
GP Pharm, S.A.
Diabetology Limited
MSM Protein Technologies, Inc.
Zealand Pharma A/S
Indus Biotech Private Limited
NOXXON Pharma AG
Omeros Corporation
Aegis Therapeutics, LLC
Peptron, Inc.
Immunocore Limited.
Molecular Design International, Inc.
PepTcell Limited
Tris Pharma, Inc.
USV Limited.
Vitae Pharmaceuticals, Inc.
Glucox Biotech
Novocell, Inc.
Diakron Pharmaceuticals, Inc.
TaiGen Biotechnology Co., Ltd.
MacuCLEAR, Inc.
KAHR medical Ltd.
Johnson and Johnson Pharmaceutical Research and Development, L.L.C.
Innocoll, Inc.
Centocor Ortho Biotech, Inc.
Adocia
Amunix, Inc.
Pharnext SAS
NGM Biopharmaceuticals, Inc.
Amplimmune, Inc.
DiscoveryBiomed, Inc.
Signum Biosciences, Inc.
Q Chip Ltd.
Nuvilex, Inc.
Revivicor, Inc.
Laila Pharmaceuticals Pvt. Ltd.
PharmaIN Corporation
AUS Bio Limited
Advancell
Madeira Therapeutics
Rhythm Pharmaceuticals

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.